| Year |
Title |
Altmetric |
| 2021
|
Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy.
Cancer Gene Therapy.
28:799-812.
2021
|
|
| 2021
|
Commentary: Developing a Professionalism and Harassment Policy for Organized Neurosurgery.
Neurosurgery.
89:E60.
2021
|
|
| 2021
|
Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas.
New England Journal of Medicine.
384:1613-1622.
2021
|
|
| 2021
|
Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas.
New England Journal of Medicine.
384:1613-1622.
2021
|
|
| 2021
|
Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant Gliomas.
Neurosurgery Clinics of North America.
32:265-281.
2021
|
|
| 2021
|
Transition From Manual to Automated Planning and Delivery of Volumetric Modulated Arc Therapy Stereotactic Radiosurgery: Clinical, Dosimetric, and Quality Assurance Results.
Practical Radiation Oncology.
11:e163-e171.
2021
|
|
| 2021
|
Gene and viral therapy for glioblastoma multiforme.
Neurosurgical Focus.
50:1-1.
2021
|
|
| 2021
|
Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomas.
Neurosurgical Focus.
50:1-11.
2021
|
|
| 2021
|
Cerebral Venous Sinus Thrombosis following Ventriculoperitoneal Shunting for Idiopathic Intracranial Hypertension.
Neuro-Ophthalmology.
2021
|
|
| 2021
|
Control and Toxicity in Melanoma Versus Other Brain Metastases in Response to Combined Radiosurgery and PD-(L)1 Immune Checkpoint Inhibition.
Advances in Radiation Oncology.
6.
2021
|
|
| 2020
|
Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy.
Nature Communications.
11.
2020
|
|
| 2020
|
Intratumoral spatial heterogeneity of BTK kinomic activity dictates distinct therapeutic response within a single glioblastoma tumor.
Journal of Neurosurgery.
133:1683-1694.
2020
|
|
| 2020
|
Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors.
Human Gene Therapy.
31:1132-1139.
2020
|
|
| 2020
|
Letter: Neurosurgeons and curves: The need for critical appraisal of modeling in the post-COVID era.
Neurosurgery.
87:E523-E524.
2020
|
|
| 2020
|
Interinstitutional Plan Quality Assessment of 2 Linac-Based, Single-Isocenter, Multiple Metastasis Radiosurgery Techniques.
Advances in Radiation Oncology.
5:1051-1060.
2020
|
|
| 2020
|
The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas.
Frontiers in Surgery.
7.
2020
|
|
| 2020
|
Emergency response plan during the COVID-19 pandemic: The University of Alabama at Birmingham experience.
Neurosurgery.
87:E218-E219.
2020
|
|
| 2020
|
Efficacy of osimertinib against EGFRvIII+ glioblastoma.
Oncotarget.
11:2074-2082.
2020
|
|
| 2020
|
Targeting MMP-14 for dual PET and fluorescence imaging of glioma in preclinical models
2020
|
|
| 2020
|
Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of mice.
Cancer Gene Therapy.
27:246-255.
2020
|
|
| 2020
|
Independent Validation of the Colloid Cyst Risk Score to Predict Symptoms and Hydrocephalus in Patients with Colloid Cysts of the Third Ventricle.
World Neurosurgery.
134:e747-e753.
2020
|
|
| 2020
|
Focal Management of Large Brain Metastases and Risk of Leptomeningeal Disease.
Advances in Radiation Oncology.
5:34-42.
2020
|
|
| 2020
|
Interrater and Intrarater Reliability of the Colloid Cyst Risk Score.
Neurosurgery.
86:E47-E53.
2020
|
|
| 2020
|
Targeted Exosomes for Drug Delivery: Biomanufacturing, Surface Tagging, and Validation.
Biotechnology Journal.
15.
2020
|
|
| 2019
|
A novel in situ multiplex immunofluorescence panel for the assessment of tumor immunopathology and response to virotherapy in pediatric glioblastoma reveals a role for checkpoint protein inhibition.
OncoImmunology.
8.
2019
|
|
| 2019
|
Repeat gamma knife stereotactic radiosurgery in the treatment of trigeminal neuralgia: A single-center experience and focused review of the literature.
Journal of Clinical Neuroscience.
70:102-107.
2019
|
|
| 2019
|
A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma.
Clinical Cancer Research.
25:5799-5807.
2019
|
|
| 2019
|
Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma.
World Neurosurgery.
129:90-100.
2019
|
|
| 2019
|
Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance.
Oncogene.
38:6159-6171.
2019
|
|
| 2019
|
Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors.
Molecular Therapy - Oncolytics.
13:14-21.
2019
|
|
| 2019
|
Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study.
PLoS Medicine.
16.
2019
|
|
| 2019
|
Phenotypic Plasticity of Invasive Edge Glioma Stem-like Cells in Response to Ionizing Radiation.
Cell Reports.
26:1893-1905.e7.
2019
|
|
| 2019
|
Stereotactic Placement of Intratumoral Catheters for Continuous Infusion Delivery of Herpes Simplex Virus -1 G207 in Pediatric Malignant Supratentorial Brain Tumors.
World Neurosurgery.
122:e1592-e1598.
2019
|
|
| 2019
|
Characterization of iPSCs derived from low grade gliomas revealed early regional chromosomal amplifications during gliomagenesis.
Journal of Neuro-Oncology.
141:289-301.
2019
|
|
| 2019
|
Current and future imaging methods for evaluating response to immunotherapy in neuro-oncology.
Theranostics.
9:5085-5104.
2019
|
|
| 2018
|
Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression.
Scientific Reports.
8.
2018
|
|
| 2018
|
The virtual cone: A novel technique to generate spherical dose distributions using a multileaf collimator and standardized control-point sequence for small target radiation surgery.
Advances in Radiation Oncology.
3:421-430.
2018
|
|
| 2018
|
Clinical Utility of Serum Procalcitonin Level and Infection in the Neurosurgical Intensive Care Unit.
World Neurosurgery.
112:e368-e374.
2018
|
|
| 2018
|
Postoperative radiosurgery for the treatment of metastatic brain tumor: Evaluation of local failure and leptomeningeal disease.
Journal of Clinical Neuroscience.
49:48-55.
2018
|
|
| 2018
|
Chimeric HCMV/HSV-1 and Δγ134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory.
Translational Oncology.
11:86-93.
2018
|
|
| 2018
|
Evaluation of multiple factors affecting normal brain dose in single-isocenter multiple target radiosurgery.
Journal of Radiosurgery and SBRT.
5:131-144.
2018
|
|
| 2017
|
Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002.
Molecular Therapy - Oncolytics.
7:27-36.
2017
|
|
| 2017
|
Primary CNS Nonamyloidogenic Light Chain Deposition Disease: Case Report and Brief Review.
International Journal of Surgical Pathology.
25:755-760.
2017
|
|
| 2017
|
Fractionated stereotactic radiation therapy for intact brain metastases.
Advances in Radiation Oncology.
2:564-571.
2017
|
|
| 2017
|
Modulation of the intratumoral immune landscape by oncolytic herpes simplex virus virotherapy.
Frontiers in Oncology.
7.
2017
|
|
| 2017
|
Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates.
Molecular Therapy - Oncolytics.
5:1-10.
2017
|
|
| 2017
|
Implications of transitioning to a resident night float system in neurosurgery: Mortality, length of stay, and resident experience.
Journal of Neurosurgery.
126:1269-1277.
2017
|
|
| 2017
|
Oncolytic Virotherapy for the Treatment of Malignant Glioma.
Neurotherapeutics.
14:333-344.
2017
|
|
| 2017
|
Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors
2017
|
|
| 2017
|
Rationale and Design of a Phase I Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.
2017
|
|
| 2017
|
Checkpoint proteins in pediatric brain and extracranial solid tumors: Opportunities for immunotherapy.
Clinical Cancer Research.
23:342-350.
2017
|
|
| 2017
|
Beyond Alkylating Agents for Gliomas: Quo Vadimus?.
American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting.
37:175-186.
2017
|
|
| 2017
|
Combination strategies enhance oncolytic virotherapy.
Oncotarget.
8:34020-34021.
2017
|
|
| 2016
|
Effect of repeat dosing of engineered oncolytic herpes simplex virus on preclinical models of rhabdomyosarcoma.
Translational Oncology.
9:419-430.
2016
|
|
| 2016
|
Interinstitutional Dosimetric Comparison Between Stereotactic Radiosurgery and Volumetric Modulated Arc Therapy Radiosurgery for Difficult Intracranial Cases.
2016
|
|
| 2016
|
Stereotactic Hypofractionated Radiation Therapy for Intact Brain Metastases.
2016
|
|
| 2016
|
Effect of resident handoffs on length of hospital and intensive care unit stay in a neurosurgical population: A cohort study.
Journal of Neurosurgery.
125:222-228.
2016
|
|
| 2016
|
Design of a Phase i Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma
2016
|
|
| 2016
|
STAT1 and NF-κB inhibitors diminish basal interferon-stimulated gene expression and improve the productive infection of oncolytic HSV in MPNST Cells
2016
|
|
| 2016
|
A phase 2 study of radiosurgery and temozolomide for patients with 1 to 4 brain metastases.
Advances in Radiation Oncology.
1:83-88.
2016
|
|
| 2016
|
Temporal-based pericranial flaps for orbitofrontal Dural repair: A technical note and Review of the literature.
Interdisciplinary Neurosurgery.
3:6-10.
2016
|
|
| 2016
|
To infection and beyond: The multi-pronged anti-cancer mechanisms of oncolytic viruses.
Viruses.
8.
2016
|
|
| 2016
|
Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses.
Neuro-Oncology.
18:227-235.
2016
|
|
| 2016
|
Effect of HSV-IL12 Loaded Tumor Cell-Based Vaccination in a Mouse Model of High-Grade Neuroblastoma.
Journal of Immunology Research.
2016.
2016
|
|
| 2015
|
Fluorescence-guided resection of experimental malignant glioma using cetuximab-IRDye 800CW.
British Journal of Neurosurgery.
29:850-858.
2015
|
|
| 2015
|
Pediatric cancer gone viral. Part I: Strategies for utilizing oncolytic herpes simplex virus-1 in children.
Molecular Therapy - Oncolytics.
2:15015.
2015
|
|
| 2015
|
Pediatric cancer gone viral. Part II: Potential clinical application of oncolytic herpes simplex virus-1 in children.
Molecular Therapy - Oncolytics.
2:15016.
2015
|
|
| 2015
|
In Reply: Volumetric Arc Therapy (RapidArc) vs Gamma Knife Radiosurgery for Multiple Brain Metastases: Not only a Dosimetric Issue.
Neurosurgery.
77:E311.
2015
|
|
| 2015
|
Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas.
Journal of Neuro-Oncology.
122:585-593.
2015
|
|
| 2015
|
Alteration of the threshold stimulus for intraoperative brain mapping via use of antiepileptic medications.
Interdisciplinary Neurosurgery.
2:16-20.
2015
|
|
| 2015
|
Erratum: [γ 1 34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia (Gene Therapy) (2015) 22: 348-355]
2015
|
|
| 2015
|
Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy..
Oncolytic Virotherapy.
4:33-38.
2015
|
|
| 2015
|
In reply: Volumetric arc therapy (RapidArc) vs Gamma knife radiosurgery for multiple brain metastases.
Neurosurgery.
76:E353-E354.
2015
|
|
| 2015
|
Intracranial blastomycotic abscess mimicking malignant brain neoplasm: Successful treatment with voriconazole and surgery.
Surgical Neurology International.
6.
2015
|
|
| 2015
|
Spontaneous cerebellar hemorrhage in a patient taking apixaban.
Interdisciplinary Neurosurgery.
2:54-56.
2015
|
|
| 2015
|
γ 1 34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia
2015
|
|
| 2014
|
Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: The University of Alabama at Birmingham experience
2014
|
|
| 2014
|
Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines
2014
|
|
| 2014
|
O-GLCNAC'S role in neurological disorders and its therapeutic implications.
Drugs of the future.
39:561-568.
2014
|
|
| 2014
|
Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide.
Radiation Oncology.
9.
2014
|
|
| 2014
|
Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells.
PLoS ONE.
9.
2014
|
|
| 2014
|
Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to Aotus Nonhuman Primates
2014
|
|
| 2014
|
Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumors.
PLoS ONE.
9.
2014
|
|
| 2014
|
A phase 1 trial of oncolytic HSV-1, g207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.
Molecular Therapy.
22:1048-1055.
2014
|
|
| 2014
|
Comparison of plan quality and delivery time between volumetric arc therapy (rapidarc) and gamma knife radiosurgery for multiple cranial metastases.
Neurosurgery.
75:409-417.
2014
|
|
| 2014
|
Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults.
Molecular Therapy.
22:1056-1062.
2014
|
|
| 2014
|
The history of neurosurgery at the university of Alabama at Birmingham.
Neurosurgery.
75:483-487.
2014
|
|
| 2013
|
Pediatric glioma stem cells: Biologic strategies for oncolytic HSV virotherapy.
Frontiers in Oncology.
3 FEB.
2013
|
|
| 2013
|
Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1.
PLoS ONE.
8.
2013
|
|
| 2013
|
Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Neuroblastoma.
PLoS ONE.
8.
2013
|
|
| 2013
|
Viral therapy of glioblastoma multiforme
2013
|
|
| 2013
|
Prognostic Relevance of Cytochrome c Oxidase in Primary Glioblastoma Multiforme.
PLoS ONE.
8.
2013
|
|
| 2012
|
Human herpesviridae methods of natural killer cell evasion.
Advances in Virology.
2012.
2012
|
|
| 2012
|
The role of early resection vs biopsy in the management of low-grade gliomas
2012
|
|
| 2012
|
Plan quality and treatment planning technique for single isocenter cranial radiosurgery with volumetric modulated arc therapy.
Practical Radiation Oncology.
2:306-313.
2012
|
|
| 2012
|
Stereotactic radiosurgical treatment of brain metastasis of primary tumors that rarely metastasize to the central nervous system.
Journal of Neuro-Oncology.
109:513-519.
2012
|
|
| 2012
|
Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12.
Journal of Virology.
86:5304-5313.
2012
|
|
| 2012
|
Hypoxia moderates γ134.5-deleted herpes simplex virus oncolytic activity in human glioma xenoline primary cultures.
Translational Oncology.
5:200-207.
2012
|
|
| 2012
|
Preclinical evaluation of oncolytic δγ(1)34.5 herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastases..
International Journal of Breast Cancer.
2012:628697.
2012
|
|
| 2012
|
Targeting pediatric cancer stem cells with oncolytic virotherapy..
Pediatric Research.
71:500-510.
2012
|
|
| 2011
|
Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1
2011
|
|
| 2011
|
Meta-analysis of hemorrhagic complications from ventriculostomy placement by neurosurgeons.
Neurosurgery.
69:255-260.
2011
|
|
| 2011
|
In reply:.
Neurosurgery.
68.
2011
|
|
| 2011
|
The relationship between INR and development of hemorrhage with placement of ventriculostomy
2011
|
|
| 2011
|
Strategies for the rapid construction of conditionally-replicating HSV-1 vectors expressing foreign genes as anticancer therapeutic agents.
Molecular Pharmaceutics.
8:44-49.
2011
|
|
| 2011
|
Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide
2011
|
|
| 2011
|
Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiforme.
Journal of Neuro-Oncology.
101:179-188.
2011
|
|
| 2011
|
Risk factors for conversion to permanent ventricular shunt in patients receiving therapeutic ventriculostomy for traumatic brain injury.
Neurosurgery.
68:85-88.
2011
|
|
| 2010
|
Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain.
Journal of Biological Chemistry.
285:39759-39767.
2010
|
|
| 2010
|
Diffusion tensor imaging in hypertrophic olivary degeneration.
American Journal of Neuroradiology.
31:1729-1731.
2010
|
|
| 2010
|
A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma.
Archives of Neurology.
67:313-319.
2010
|
|
| 2010
|
Impact of Dose Rate on Outcomes of Gamma Knife® Radiosurgery in Patients with Face Pain.
Radiosurgery.
7:360-365.
2010
|
|
| 2009
|
CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.
Cancer Gene Therapy.
16:794-805.
2009
|
|
| 2009
|
Characterization and immunotherapeutic potential of γδ T-cells in patients with glioblastoma.
Neuro-Oncology.
11:357-367.
2009
|
|
| 2009
|
Oncolytic Viral Therapy of Malignant Glioma.
Neurotherapeutics.
6:558-569.
2009
|
|
| 2009
|
Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111.
Journal of Neuro-Oncology.
95:199-209.
2009
|
|
| 2009
|
A phase I study of ABT 510 and concurrent temozolamide and radiotherapy for patients with newly diagnosed glioblastoma multiforme..
Journal of Clinical Oncology.
27:2023.
2009
|
|
| 2009
|
Treatment of recurrent malignant glioma with G207, a genetically engineered herpes simplex virus-1, followed by irradiation: Phase I study results..
Journal of Clinical Oncology.
27:2042.
2009
|
|
| 2009
|
Herpes simplex virus oncolytic therapy for pediatric malignancies.
Molecular Therapy.
17:1125-1135.
2009
|
|
| 2009
|
Cancer of the tonsil presenting as central nervous system metastasis: A case report
2009
|
|
| 2009
|
Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM.
Molecular Therapy.
17:199-207.
2009
|
|
| 2008
|
Hitting a moving target: Evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria.
Neurosurgical Focus.
24.
2008
|
|
| 2008
|
Erratum: Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma (Gene Therapy (2008) vol. 14 (1111-1119) 10.1038/sj.gt.3302965)
2008
|
|
| 2008
|
A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.
Molecular Therapy.
16:627-632.
2008
|
|
| 2008
|
Predictors of Distant Brain Recurrence for Patients With Newly Diagnosed Brain Metastases Treated With Stereotactic Radiosurgery Alone
2008
|
|
| 2007
|
Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses
2007
|
|
| 2007
|
Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain.
Journal of NeuroVirology.
13:118-129.
2007
|
|
| 2007
|
Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors.
Cancer Gene Therapy.
14:45-56.
2007
|
|
| 2007
|
Necrotizing neurosarcoid: Three cases with varying presentations.
Clinical Neuropathology.
26:59-67.
2007
|
|
| 2006
|
Oncolytic HSV-1 for the treatment of brain tumours
2006
|
|
| 2006
|
Serial passage through human glioma xenografts selects for a Δγ134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors.
Journal of Virology.
80:7308-7315.
2006
|
|
| 2006
|
Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cells.
Journal of Biological Chemistry.
281:19220-19232.
2006
|
|
| 2006
|
Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates.
Vaccine.
24:1644-1652.
2006
|
|
| 2006
|
Bilateral metastatic renal hemangiopericytoma ten years after primary intracranial lesion.
International Brazilian Journal of Urology.
32:306-307.
2006
|
|
| 2006
|
Dexmedetomidine as rescue drug during awake craniotomy for cortical motor mapping and tumor resection.
Anesthesia and Analgesia.
102:1556-1558.
2006
|
|
| 2005
|
Polymerase chain reaction for the rapid detection of cerebrospinal fluid shunt or ventriculostomy infections.
Neurosurgery.
57:1237-1242.
2005
|
|
| 2005
|
Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model.
Neuro-Oncology.
7:213-224.
2005
|
|
| 2005
|
Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12.
Cancer Gene Therapy.
12:359-368.
2005
|
|
| 2004
|
A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.
Molecular Therapy.
10:958-966.
2004
|
|
| 2004
|
Cation selectivity and inhibition of malignant glioma Na+ channels by Psalmotoxin 1
2004
|
|
| 2004
|
Initial treatment of melanoma brain metastases using gamma knife radiosurgery: An evaluation of efficacy and toxicity.
Cancer.
101:825-833.
2004
|
|
| 2004
|
Biologic warfare for a good cause: HSV-1 anti-tumor therapy..
Clinical Neurosurgery.
51:73-80.
2004
|
|
| 2004
|
Brain metastases.
Current Problems in Surgery.
41:665-741.
2004
|
|
| 2003
|
Oncolytic viruses: Clinical applications as vectors for the treatment of malignant gliomas.
Journal of Neuro-Oncology.
65:203-226.
2003
|
|
| 2003
|
Molecular cloning and characterization of human acid sensing ion channel (ASIC)2 gene promoter.
Gene.
313:91-101.
2003
|
|
| 2003
|
Glioblastoma multiforme: Introduction
2003
|
|
| 2003
|
Acid-sensing ion channels in malignant gliomas.
Journal of Biological Chemistry.
278:15023-15034.
2003
|
|
| 2003
|
Glioblastoma multiforme: Introduction
2003
|
|
| 2002
|
Protein kinase C isoform antagonism controls BNaC2 (ASIC1) function.
Journal of Biological Chemistry.
277:45734-45740.
2002
|
|
| 2002
|
The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma
2002
|
|
| 2002
|
The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma
2002
|
|
| 2001
|
pH Alterations "Reset" Ca2+ Sensitivity of Brain Na+ Channel 2, a Degenerin/Epithelial Na+ Ion Channel, in Planar Lipid Bilayers.
Journal of Biological Chemistry.
276:38755-38761.
2001
|
|
| 2001
|
Genetically engineered human herpes simplex virus in the treatment of brain tumours
2001
|
|
| 2001
|
Differential gene expression profiling in human brain tumors.
Physiological Genomics.
2001:21-33.
2001
|
|
| 2000
|
Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.
2000
|
|
| 2000
|
Genetically engineered HSV in the treatment of glioma: A review.
Reviews in Medical Virology.
10:17-30.
2000
|
|
| 2000
|
Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors
2000
|
|
| 2000
|
Conditionally replicating herpes simplex virus mutant G207 for the treatment of malignant glioma: Results of a phase I trial
2000
|
|
| 1999
|
Ionizing radiation improves survival in mice bearing intracranial high- grade gliomas injected with genetically modified herpes simplex virus.
Clinical Cancer Research.
5:1517-1522.
1999
|
|
| 1999
|
Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors.
Cancer Research.
59:2055-2058.
1999
|
|
| 1998
|
Nonsurgical management of upper cervical spine injuries.
Techniques in Neurosurgery.
4:268-277.
1998
|
|
| 1998
|
Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins
1998
|
|
| 1997
|
Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
Cancer Research.
57:1502-1509.
1997
|
|
| 1996
|
The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors
1996
|
|
| 1996
|
Use of the extreme lateral approach in the surgical treatment of an intradural ventral cervical spinal cord vascular malformation: Technical case report.
Neurosurgery.
38:412-415.
1996
|
|
| 1996
|
Spontaneous CSF fistula through a congenitally fenestrated sphenoid bone.
American Journal of Roentgenology.
166:952-954.
1996
|
|
| 1995
|
Primary osseous amyloidoma causing spinal cord compression.
American Journal of Neuroradiology.
16:1152-1154.
1995
|
|
| 1994
|
CNS tumor therapy by attenuated herpes simplex viruses.
1994
|
|
| 1993
|
Paroxysmal bilateral dysosmia treated by resection of the olfactory bulbs.
Surgical Neurology.
40:160-163.
1993
|
|
| 1993
|
Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir.
Neurosurgery.
32:597-603.
1993
|
|
| 1992
|
Expanded spectrum of viral therapy in the treatment of nervous system tumors.
Journal of Neurosurgery.
77:590-594.
1992
|
|
| 1991
|
Experimental therapy of human glioma by means of a genetically engineered virus mutant.
Science.
252:854-856.
1991
|
|
